Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18049571 | 0.84 | L3MBTL1 (0.42) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL18049623 | 0.84 | L3MBTL1 (0.46) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL1559603 | 0.80 | L3MBTL1 (0.48) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL28125498 | 0.80 | L3MBTL1 (0.44) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL19207788 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPTLMNAMITF | |
| SCHEMBL18418903 | 0.77 | L3MBTL1 (0.42) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL2183233 | 0.77 | L3MBTL1 (0.42) | L3MBTL1ALDH1A1MAPTPOLBLMNA | |
| SCHEMBL19207586 | 0.76 | TNF (0.48) | SMN1; SMN2L3MBTL1ALDH1A1MAPTPOLB | |
| SCHEMBL21964566 | 0.73 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1MAPTPOLBLMNA | |
| SCHEMBL13294997 | 0.73 | USP2 (0.34) | SMN1; SMN2L3MBTL1POLBPDE5ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103044330-B | The new green synthesizing process of silaenafil intermediate 4- amino -1- methyl -3- n-propyl pyrazoles -5- formamides | 常州亚邦制药有限公司 | 2018-11-13 | — | — | CN | disclosed |
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-6444816-B1 | DIETETICS, ANTICHOLESTEROL AGENTS, ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194529-A1 | HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS | PDE5A, PDE7A, PDE3A | SMN1; SMN2 1886/4885L3MBTL1 4848/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.